Tumour markers as seen from the clinical laboratory: physiological, biochemical, and analytical aspects

References

• Minton J P, Chevinsky A. Present status of serum markers. Sem Surg Oncol 1989; 5: 426–35
   PubMedGoogle Scholar
• Matsuoka Y, Matsuo Y, Sugano K, Ohkura H, Kuroki M. Characterization of carcinoembryonic antigen-related antigens in normal adult feces. Jpn J Cancer Res 1990; 81: 514–9
   PubMedGoogle Scholar
• Cournoyer D, Beauchemin N, Boucher D, Benchimol S, Fuks A, Stanners CP. Transcription of genes of the carcinoembryonic antigen family in malignant and nonmalignant human tissues. Cancer Res 1988; 48: 3153–7
   PubMed Web of Science ®Google Scholar
• Thompson J, Zimmermann W. The carcinoembryonic antigen gene family: Structure, expression and evolution. Tumor Biol 1988; 9: 63–83
   PubMed Web of Science ®Google Scholar
• Marrink J, Sleijfer D T, de Vries E GE, Koops HS. Alphafetoprotein-lectin binding as a marker of tumour activity or liver damage. Eur J Cancer 1990; 26: 969–72
   PubMedGoogle Scholar
• Touitou Y, Bogdan A. Tumor markers in non-malignant diseases. Eur J Cancer 1988; 24: 1083–91
   Google Scholar
• Bormer OP. Standardization, specificity, and diagnostic sensitivity of four immunoassays for carcinoembryonic antigen. Clin Chem 1991; 37: 231–6
   PubMedGoogle Scholar
• Lokich JE, Uenberg S, Gerson B, Knox W E, Zamcheck N. Plasma clearance of carcinoembryonic antigen following hepatic metastatectomy. Clin Oncol 1984; 2: 462–5
   Google Scholar
• Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer DetPrev 1988; 12: 321–55
   Google Scholar
• Horwich A, Peckham MJ. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Rep 1986; 70: 1329–31
   PubMedGoogle Scholar
• Vergote I P, Börmer O P, Abeler V. Eavaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 1987; 157: 88–92
   PubMed Web of Science ®Google Scholar
• Thomas P, Toth C A, Saini K S, Jessup J M, Steele G. The structure, metabolism and function of the carcinoembryonic antigen gene family. Biochim Biophys Acta 1990; 1032: 177–89
   PubMedGoogle Scholar
• Riesen W, Kessler A C, Ehrhardt V. Individual variations of carcinoembryoni antigen (CEA) in serum of healthy subjects. Clin Chem 1987; 33: 2123
   PubMedGoogle Scholar
• Jackson T M, Ekins RP. Theoretical limitations of immunoassay sensitivity. Current practice and potential advantages of fluorescent Eu 3+ chelates as non-radioisotopic tracers. J Immunol Methods 1986; 87: 13–20
   PubMed Web of Science ®Google Scholar
• Ekins R. Is immunoassay standardization possible? (Abstract). Clin Chem 1990; 36: 1245
   Google Scholar
• Börmer O P, Nustad K. Selection of monoclonal antibodies for use in an immunometric assay for carcinoembryonic antigen. J Immunol Methods 1990; 127: 171–8
   PubMed Web of Science ®Google Scholar
• Hedin A, Carlsson L, Berglund A, Hammarstrom S. A monoclonal antibody-enzyme immunoassay for serum carcinoembryonic antigen with increased specificity for carcinomas. Proc Natl Acad Sci USA 1983; 80: 3470–4
   PubMed Web of Science ®Google Scholar
• Hammarström S, Shively JE, Paxton RJ, Beatty BG, Larsson Å, Ghosh R, Börmer O, Buchegger F, Mach J-P, Burtin P, Seguin P, Darbouret B, Degorce F, Sertour J, Jolu JP, Fuks A, Kalthoff H, Schmiegel W, Amdt R, Kloppel G, von Kleist S, Gnmert F, Schwarz K, Matsuoka Y, Kuroki M, Wagener C, Weber T, Yachi A, Imai K, Hishikawa N, Tsujisaki M. Antigenic sites in carcinoembryonic antigen. Cancer Res 1989; 49: 4852–8
   PubMed Web of Science ®Google Scholar
• Börmer O P, Thrane-Steen K. Epitope group specificity of six immunoassays for carcinoembryonic antigen. Tumor Biol 1991; 12: 9–15
   PubMedGoogle Scholar
• Paus E, Fosså A, Fosså SD, Nustad K. High frequency of incomplete human chorionic gonadotropin in patients with testicular seminoma. J Urol 1988; 139: 542–4
   PubMedGoogle Scholar
• Paus E, Nustad K. Immunoradiometric assay for ag - and gg-enolase (neuron-specific enolase), with use of monoclonal antibodies and magnetizable polymer particles. Clin Chem 1989; 35: 2034–8
   PubMed Web of Science ®Google Scholar
• Bormer OP. Interference of complement with the binding of carcinoembryonic antigen to solid-phase monoclonal antibodies. J Immunol Methods 1989; 121: 85–93
   PubMed Web of Science ®Google Scholar
• Boscato L M, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem 1986; 32: 1491–5
   PubMed Web of Science ®Google Scholar
• Gosling JP. A decade of development in immunoassay methodology. Clin Chem 1990; 36: 1408–27
   PubMed Web of Science ®Google Scholar
• Silver H K, Archibald B-L, Ragaz J, Coldman AJ. Relative operating characteristic analysis and group modeling for tumor markers: Comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma. Cancer Res 1991; 51: 1904–9
   PubMed Web of Science ®Google Scholar
• Catalona W J, Smith D S, Ratliff T L, Dodds K M, Coplen D E, Yuan J JJ, Petros J A, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Eng J Med 1991; 324: 1156–61
   PubMed Web of Science ®Google Scholar
• Joss R, Cerny T. Sinn und Unsinn von Tumormarkern in der Praxis. Schweiz med Wschr 1990; 120: 693–703
   PubMedGoogle Scholar
• Sell S. Cancer markers of the 1990s. Clinics Lab Med 1990; 10: 1–37
   PubMedGoogle Scholar
• Hass G M, Boiling T J, Kinders R J, Henslee J G, Mandecki W, Dorwin S A, Shively JE. Preparation of synthetic polypeptide domains of carcinoembryonic antigen and their use in epitope mapping. Cancer Res 1991; 51: 1876–82
   PubMedGoogle Scholar